Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03888105
Recruitment Status : Recruiting
First Posted : March 25, 2019
Last Update Posted : March 30, 2020
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

Primary objective is to assess the anti-tumor activity of single agent REGN1979 as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in each of the following B-cell non-Hodgkin lymphoma (B-NHL) subgroups:

  • In patients with follicular lymphoma (FL) grade 1-3a *1,3
  • In patients with diffuse large B-cell lymphoma (DLBCL) *1,3
  • In patients with mantle cell lymphoma (MCL) that has relapsed after or is refractory to a BTK inhibitor. This cohort will also include patients who have relapsed or have disease refractory to prior systemic therapy, or patients who have demonstrated intolerance to BTK inhibitor therapy, and who have progressed after other systemic therapy.
  • In patients with marginal zone lymphoma (MZL) *2
  • In patients with other B-NHL subtypes *2, including an anti-CD20 antibody. However, patients with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma) are excluded from this study.

Secondary objectives are:

  • To assess the anti-tumor activity of single agent REGN1979 in each of 5 disease-specific cohorts, as measured by:
  • ORR according to the Lugano Classification and as assessed by local investigator evaluation
  • Complete response (CR) rate according to the Lugano Classification and as assessed local by local investigator evaluation and independent central review
  • Progression-free survival (PFS)*4
  • Overall survival (OS)
  • Duration of response (DOR)*4
  • Disease control rate (DCR)*4
  • Duration of disease control (DODC)*4
  • To evaluate the safety and tolerability of REGN1979
  • To assess the pharmacokinetics (PK) of REGN1979
  • To assess the immunogenicity of REGN1979
  • To assess the effect of REGN1979 on patient reported outcomes, including health-related quality of life (HRQL), as measured by the validated instruments European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), and EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L)

    • 1 that has relapsed after or is refractory to at least 2 prior lines of systemic therapy
    • 2 that has relapsed after or is refractory to at least 1 prior line of systemic therapy
    • 3 including an anti-CD20 antibody and an alkylating agent.
    • 4 according to Lugano Classification and as assessed by independent central review and local investigator evaluation

Condition or disease Intervention/treatment Phase
B-cell Non-Hodgkin Lymphoma (NHL) Drug: REGN1979 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 497 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 5 cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Actual Study Start Date : November 13, 2019
Estimated Primary Completion Date : January 6, 2025
Estimated Study Completion Date : January 6, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: FL
Follicular lymphoma grade 1-3a cohort
Drug: REGN1979
Administered by intravenous (IV) infusion

Experimental: DLBCL
Diffuse large B-cell lymphoma cohort
Drug: REGN1979
Administered by intravenous (IV) infusion

Experimental: MCL
Mantle Cell Lymphoma cohort
Drug: REGN1979
Administered by intravenous (IV) infusion

Experimental: MZL
Marginal Zone Lymphoma cohort
Drug: REGN1979
Administered by intravenous (IV) infusion

Experimental: Other B-NHL
Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM])
Drug: REGN1979
Administered by intravenous (IV) infusion




Primary Outcome Measures :
  1. ORR [ Time Frame: From first patient first dose until all patients have completed 28 weeks of study treatment or have withdrawn from the study ]
    For each of the 5 disease-specific cohorts according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review.


Secondary Outcome Measures :
  1. ORR [ Time Frame: First patient first dose until all patients have completed 28 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification, as assessed by local investigator evaluation

  2. CR rate [ Time Frame: First patient first dose until all patients have completed 28 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by local investigator evaluation and independent central review

  3. PFS [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation

  4. OS [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
  5. DOR [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation

  6. DCR [ Time Frame: First patient first dose until all patients have completed 28 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation

  7. DODC [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation

  8. Incidence and severity of treatment emergent adverse events (TEAEs) [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
  9. Pharmacokinetics: Concentration of REGN1979 [ Time Frame: 12 weeks following end of treatment ]
    End of infusion [EOI]; Concentration at a specified time t [Ct])

  10. Immunogenicity: Anti-REGN1979 antibodies [ Time Frame: 12 weeks following end of treatment ]
  11. Changes in scores of patient-reported outcomes as measured by EORTC QLQ-C30 [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).

  12. Changes in scores of patient-reported outcomes as measured by FACT-Lym [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    Composed of the FACT-G plus the 15-item Lymphoma Subscale (LymS).

  13. Changes in scores of patient-reported outcomes as measured by EQ-5D-3L [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

For the FL grade 1-3a cohort only:

  • Central histopathologic confirmation of the FL Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL grade 3b are ineligible for this cohort but may be included in the "other B-NHL" cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO) classification (Swerdlow, 2017).
  • Disease-specific cohorts that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
  • DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
  • MCL after BTK inhibitor therapy cohort: Patients with MCL who have relapsed after or are refractory to a BTK inhibitor as defined in the protocol
  • MZL cohort: Patients with MZL that has relapsed after or is refractory to at least 1 prior line of systemic therapy as defined in the protocol
  • Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL that has relapsed after or is refractory to at least 1 prior line of systemic therapy as defined in the protocol
  • Patients should in the judgment of the investigator require systemic therapy for lymphoma at the time of study enrollment
  • Measurable disease on cross sectional imaging as defined in the protocol documented by diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI))
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate bone marrow, hepatic, and renal function as defined in the protocol

Key Exclusion Criteria:

  • Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar puncture, as appropriate, in addition to the mandatory head CT or MRI).
  • Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28 days prior to first administration of study drug, whichever is shorter.
  • History of allogeneic stem cell transplantation
  • Prior treatment with any chimeric antigen receptor T-cell (CAR-T) therapy
  • Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug
  • History of neurodegenerative condition or CNS movement disorder. Patients with a history of seizure within 12 months prior to study enrollment are excluded
  • Another malignancy except FL in the past 5 years, with the exception of non-melanoma skin cancer that has undergone potentially curative therapy or in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent.
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or other uncontrolled infection as defined in the protocol
  • Known hypersensitivity to both allopurinol and rasburicase
  • Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy

Note: Other protocol-defined Inclusion/Exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03888105


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Locations
Show Show 48 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals

Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03888105    
Other Study ID Numbers: R1979-ONC-1625
2017-002139-41 ( EudraCT Number )
First Posted: March 25, 2019    Key Record Dates
Last Update Posted: March 30, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access Criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
URL: https://errs.regeneron.com/external

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Relapsed B-NHL
Refractory B-NHL
NHL
FL
DLBCL
MZL
MCL
bispecific antibody
CD20
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Bispecific
Immunologic Factors
Physiological Effects of Drugs